This page has only limited features, please log in for full access.

Unclaimed
Alexandra M. Stevens
Texas Children’s Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX 77030, USA

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

The user biography is not available.
Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Editorial
Published: 12 August 2021 in Children
Reads 0
Downloads 0

This Special Issue brings together an original research report, a fascinating case report, and three timely reviews on a variety of topics related to pediatric leukemia

ACS Style

Alexandra M. Stevens; Michele S. Redell. Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions. Children 2021, 8, 698 .

AMA Style

Alexandra M. Stevens, Michele S. Redell. Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions. Children. 2021; 8 (8):698.

Chicago/Turabian Style

Alexandra M. Stevens; Michele S. Redell. 2021. "Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions." Children 8, no. 8: 698.

Case report
Published: 28 May 2020 in Children
Reads 0
Downloads 0

Transient abnormal myelopoiesis (TAM) is a common and potentially fatal neonatal complication of newborn babies with Down syndrome (DS). Children born with mosaic DS are also at risk of developing TAM. However, due to their variable phenotypes, early identification of patients with mosaic DS may be difficult; thus, early diagnosis of TAM is just as challenging. In this report, we describe a case of a phenotypically normal newborn who presented with concerns for neonatal leukemia. The diagnosis of mosaic DS and TAM was confirmed with abnormal GATA1 mutation testing, highlighting the importance of early GATA1 mutation testing in newborn leukemia with high suspicion for TAM.

ACS Style

Zachary Prudowsky; Hyojeong Han; Alexandra Stevens. Transient Abnormal Myelopoeisis and Mosaic down Syndrome in a Phenotypically Normal Newborn. Children 2020, 7, 52 .

AMA Style

Zachary Prudowsky, Hyojeong Han, Alexandra Stevens. Transient Abnormal Myelopoeisis and Mosaic down Syndrome in a Phenotypically Normal Newborn. Children. 2020; 7 (6):52.

Chicago/Turabian Style

Zachary Prudowsky; Hyojeong Han; Alexandra Stevens. 2020. "Transient Abnormal Myelopoeisis and Mosaic down Syndrome in a Phenotypically Normal Newborn." Children 7, no. 6: 52.

Review
Published: 02 February 2020 in Children
Reads 0
Downloads 0

Acute promyelocytic leukemia (APL) is a rare disease accounting for only 5%–10% of pediatric acute myeloid leukemia (AML) and fewer than 1000 cases occur annually in the United States across all age groups. Characterized by t (15; 17), with a resultant PML-RARA gene fusion driving leukemia development, advances in therapy have improved outcomes for APL significantly in the past several decades, now making APL the most curable form of AML in both children and adults. Cure rates in APL are now comparable to pediatric B-lymphoid leukemias. The success of APL treatment is due, in part, to the breadth of understanding of the driver PML-RARA mutation as well as collaborative efforts to quickly introduce and maximize the benefit of new therapies. Here, we review the presentation, clinical features, pathogenesis, and treatment advances in pediatric APL.

ACS Style

Shannon Conneely; Alexandra Stevens. Advances in Pediatric Acute Promyelocytic Leukemia. Children 2020, 7, 11 .

AMA Style

Shannon Conneely, Alexandra Stevens. Advances in Pediatric Acute Promyelocytic Leukemia. Children. 2020; 7 (2):11.

Chicago/Turabian Style

Shannon Conneely; Alexandra Stevens. 2020. "Advances in Pediatric Acute Promyelocytic Leukemia." Children 7, no. 2: 11.